Dr. Reddy's Laboratories/$RDY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Dr. Reddy's Laboratories
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Ticker
$RDY
Sector
Primary listing
NYSE
Employees
27,811
Headquarters
Hyderabad, India
Website
RDY Metrics
BasicAdvanced
$12B
18.68
$0.77
0.32
$0.07
0.49%
Price and volume
Market cap
$12B
Beta
0.32
52-week high
$16.17
52-week low
$12.26
Average daily volume
993K
Dividend rate
$0.07
Financial strength
Current ratio
1.893
Quick ratio
1.156
Long term debt to equity
1.441
Total debt to equity
13.751
Dividend payout ratio (TTM)
11.73%
Interest coverage (TTM)
23.72%
Profitability
EBITDA (TTM)
1,015.55
Gross margin (TTM)
57.65%
Net profit margin (TTM)
16.99%
Operating margin (TTM)
21.73%
Effective tax rate (TTM)
25.44%
Revenue per employee (TTM)
$136,540
Management effectiveness
Return on assets (TTM)
9.71%
Return on equity (TTM)
17.71%
Valuation
Price to earnings (TTM)
18.679
Price to revenue (TTM)
3.169
Price to book
2.99
Price to tangible book (TTM)
4.31
Price to free cash flow (TTM)
69.823
Free cash flow yield (TTM)
1.43%
Free cash flow per share (TTM)
0.207
Dividend yield (TTM)
0.49%
Forward dividend yield
0.49%
Growth
Revenue change (TTM)
15.86%
Earnings per share change (TTM)
2.18%
3-year revenue growth (CAGR)
15.43%
10-year revenue growth (CAGR)
8.30%
3-year earnings per share growth (CAGR)
23.96%
10-year earnings per share growth (CAGR)
9.77%
3-year dividend per share growth (CAGR)
10.06%
10-year dividend per share growth (CAGR)
7.18%
What the Analysts think about RDY
Analyst ratings (Buy, Hold, Sell) for Dr. Reddy's Laboratories stock.
Bulls say / Bears say
Dr. Reddy’s European revenue more than doubled in Q2 FY25, driven by strong demand for the Nicotine Replacement Therapy portfolio acquired from Haleon, underscoring successful diversification beyond generics (Reuters)
Dr. Reddy’s plans to launch generic Wegovy in 87 countries starting next year, positioning the company to capture share in the rapidly growing obesity drug market projected to reach $150 billion by the early 2030s (Reuters)
As of June 2025, Dr. Reddy’s had 73 pending ANDA filings with the U.S. FDA, including 43 Paragraph IVs and 22 with first-to-file potential, ensuring a robust pipeline for future generics launches in North America (Business Standard)
Revenue in North America fell 11.3% in Q2 FY25 due to price erosion in key products like Lenalidomide, revealing significant vulnerability in Dr. Reddy’s largest market (Reuters)
Dr. Reddy’s narrow profit miss in Q2 FY25, with net earnings of ₹14.18 billion versus ₹14.94 billion estimated, underscores margin pressure from intensifying generic competition (Reuters)
The upcoming patent expiries for semaglutide will trigger intense competition in the obesity drug segment from peers such as Biocon, Cipla, and Lupin, potentially compressing Dr. Reddy’s pricing power and margins (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
RDY Financial Performance
Revenues and expenses
RDY Earnings Performance
Company profitability
RDY News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Dr. Reddy's Laboratories stock?
Dr. Reddy's Laboratories (RDY) has a market cap of $12B as of October 20, 2025.
What is the P/E ratio for Dr. Reddy's Laboratories stock?
The price to earnings (P/E) ratio for Dr. Reddy's Laboratories (RDY) stock is 18.68 as of October 20, 2025.
Does Dr. Reddy's Laboratories stock pay dividends?
Yes, the Dr. Reddy's Laboratories (RDY) stock pays dividends to shareholders. As of October 20, 2025, the dividend rate is $0.07149 and the yield is 0.49%. Dr. Reddy's Laboratories has a payout ratio of 11.73% on a trailing twelve-month basis.
When is the next Dr. Reddy's Laboratories dividend payment date?
The next Dr. Reddy's Laboratories (RDY) dividend payment date is unconfirmed.
What is the beta indicator for Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories (RDY) has a beta rating of 0.32. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.